News
-
3 March 2021
ObvioHealth and RedHill to begin remote Covid-19 therapy trial
ObvioHealth is set to initiate a Phase II/III study of RedHill Biopharma’s RHB-107 (upamostat) in the US for Covid-19 treatment.
-
3 March 2021
NIH pauses Covid-19 convalescent plasma trial
The US National Institutes of Health (NIH) has put on hold a trial of convalescent blood plasma in treating patients with mild-to-moderate Covid-19 symptoms as the study provided no significant...
-
2 March 2021
Veru to progress Covid-19 drug into Phase III study
Veru is all set to advance its drug, VERU-111, into a Phase III registration clinical study in hospitalised high-risk Covid-19 patients on obtaining clinically meaningful benefits in a Phase II...
-
1 March 2021
Partner Therapeutics’ inhaled sargramostim improves lung function in trial
Partner Therapeutics has reported positive top-line results from the investigator-led study of inhaled Leukine (sargramostim) in hospitalised Covid-19 patients.
-
26 February 2021
Atossa reports positive results from Covid-19 nasal spray study
Atossa Therapeutics has reported positive final results from the Phase I clinical study of AT-301 nasal spray being developed to reduce Covid-19 symptoms in patients already diagnosed with the disease.
-
26 February 2021
Leidos to conduct clinical trials for Covid-19 therapeutics
The Defense Threat Reduction Agency (DTRA) in the US has awarded a new project agreement to Leidos to conduct clinical trials for Covid-19 therapeutics.
-
26 February 2021
Pfizer and BioNTech to test Covid-19 vaccine against new variants
Pfizer and BioNTech have initiated a new trial to determine the efficacy of the third dose of their Covid-19 vaccine (BNT162b2) against emerging SARS-CoV-2 variants.
-
26 February 2021
GSK to amend Covid-19 study to confirm efficacy in older patients
GlaxoSmithKline (GSK) has decided to amend a Covid-19 study that seeks to determine the effectiveness of a fully human monoclonal antibody, Otilimab, in treating hospitalised adult patients with Covid-19.
-
25 February 2021
Constant Therapeutics’ drug enters Phase II trial for Covid-19 in Israel
Israel’s Rambam Medical Health Care Campus and Ziv Medical Center researchers have begun a Phase II clinical trial of Constant Therapeutics’ lead drug candidate, TXA27, for Covid-19.
-
25 February 2021
Takeda doses first subject in Japanese Covid-19 vaccine trial
Takeda Pharmaceutical has dosed the first subject in its Phase I/II study of Novavax’s Covid-19 vaccine candidate, TAK-019, in Japan.